Sumiki'S Acid

Sumiki'S Acid

SCHEMBL50822

O=C(O)c1ccc(CO)o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 1.00
ALDH1A1 P00352 3/20 0.59
TSHR P16473 1/20 0.59
POLB P06746 7/20 0.56
L3MBTL1 Q9Y468 2/20 0.51
MAPT P10636 2/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
MAPK1 P28482 1/20 0.50
KMT2A Q03164 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ESR1 P03372 1/20 0.49
NR4A1 P22736 1/20 0.49
APEX1 P27695 1/20 0.49
RECQL P46063 1/20 0.49
DUSP3 P51452 1/20 0.49
PTPN5 P54829 1/20 0.49
PTPN11 Q06124 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sumiki'S Acid SCHEMBL29706392 1.00 TDP1 (1.00) TDP1ALDH1A1TSHRPOLBL3MBTL1
SCHEMBL901472 0.84 TDP1 (0.72) TDP1ALDH1A1POLBL3MBTL1MAPT
Sumiki'S Acid SCHEMBL28619852 0.83 TDP1 (0.69) TDP1ALDH1A1TSHRPOLBL3MBTL1
SCHEMBL27313148 0.83 TDP1 (0.70) TDP1ALDH1A1POLBL3MBTL1MAPT
SCHEMBL8610246 0.82 TDP1 (0.69) TDP1ALDH1A1POLBL3MBTL1MAPT
SCHEMBL6447185 0.82 TDP1 (0.69) TDP1ALDH1A1TSHRPOLBL3MBTL1
Aes-103 SCHEMBL28643076 0.82 ALDH1A1 (0.73) TDP1ALDH1A1TSHRPOLBL3MBTL1
SCHEMBL4442918 0.80 TDP1 (0.67) TDP1ALDH1A1POLBL3MBTL1MAPT
SCHEMBL3562210 0.80 TDP1 (0.67) TDP1ALDH1A1POLBL3MBTL1MAPT
SCHEMBL183409 0.80 TDP1 (0.67) TDP1ALDH1A1POLBL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1715 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3778580-B1 SYNTHESIS OF FURANS FROM SUGARS VIA KETO INTERMEDIATES BP CORP NORTH AMERICA INC (US) 2025-12-17 EP claimed
EP-4649073-A1 METHOD OF OXIDIZING ALDEHYDES Resource Chemical Corporation (US) 2025-11-19 EP claimed
US-20250320534-A1 COMPOSITIONS AND METHODS FOR PRODUCING DIHYDROFURANS FROM KETO-SUGARS ARZEDA CORP (US) 2025-10-16 US claimed
US-20250197367-A1 PROCESS FOR THE OXIDATION OF HYDROXYMETHYLFURFURAL Südzucker AG (DE) 2025-06-19 US claimed
CN-116637634-B Preparation and application of furanmethanol compound hydrogenolysis catalyst 南昌大学 2025-06-13 CN claimed
CN-120058655-A Preparation method of 5-hydroxymethyl furoic acid 莆田达凯新材料有限公司 2025-05-30 CN claimed
CN-120041518-A Method for synthesizing furan acid compound by catalyzing 5-hydroxymethylfurfural through chemical enzyme cascade 南京工业大学 2025-05-27 CN claimed
CN-119985789-A Method for simultaneously measuring 5-hydroxymethylfurfural and oxidation products thereof 中国科学院宁波材料技术与工程研究所 2025-05-13 CN claimed
CN-119915931-A HPLC (high Performance liquid chromatography) characteristic spectrum construction method for pollen typhae medicinal materials, fried pollen typhae decoction pieces, standard decoction and prescription granule thereof 四川厚宇中药有限公司 2025-05-02 CN claimed
US-20250136566-A1 FURAN DICARBOXYLIC ACID COMPOUND, METHOD FOR PREPARING FURAN DICARBOXYLIC ACID COMPOUND, POLYESTER, AND MEHTOD FOR PREPARING POLYESTER KOLON INDUSTRIES, INC. (KR) 2025-05-01 US claimed
EP-1834951-A1 Method for the synthesis of organic acid esters of 5-hydroxymethylfurfural and their use Avantium International B.V. (NL) 2007-09-19 EP claimed
US-20070185096-A1 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein NOVARTIS PHARMACEUTICALS CORPORATION (US) 2007-08-09 US claimed
CN-1933841-A Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein ARROW THERAPEUTICS LTD (GB) 2007-03-21 CN claimed
CN-1929848-A Benzodiazepines for treating or preventing or preventing RSV infection ARROW THERAPEUTICS LTD (GB) 2007-03-14 CN claimed
EP-1740185-A1 BENZODIAZEPINES FOR TREATING OR PREVENTING RSV INFECTION Arrow Therapeutics Limited (GB) 2007-01-10 EP claimed
EP-1727551-A1 PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN Arrow Therapeutics Limited (GB) 2006-12-06 EP claimed
WO-2005089770-A1 BENZODIAZEPINES FOR TREATING OR PREVENTING OR PREVENTING RSV INFECTION ARROW THERAPEUTICS LIMITED (GB) 2005-09-29 WO claimed
WO-2005090319-A1 PROCESS FOR PREPARING BENZODIAZEPINES ARROW THERAPEUTICS LIMITED (GB) 2005-09-29 WO claimed
WO-2005089771-A1 PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN ARROW THERAPEUTICS LIMITED (GB) 2005-09-29 WO claimed
US-5686311-A ANALYZING FLUID SAMPLE THE CHILDREN'S MERCY HOSPITAL (US) 1997-11-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185096-A1 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein GABRP, TSPO, GABRA1 TDP1 3562/4885ALDH1A1 3840/4885TSHR 2549/4885
US-20250320534-A1 COMPOSITIONS AND METHODS FOR PRODUCING DIHYDROFURANS FROM KETO-SUGARS DERA, KHK, HK2 TDP1 1840/4885ALDH1A1 1298/4885TSHR 4763/4885
US-20250136566-A1 FURAN DICARBOXYLIC ACID COMPOUND, METHOD FOR PREPARING FURAN DICARBOXYLIC ACID COMPOUND, POLYESTER, AND MEHTOD FOR PREPARING POLYESTER HADH, DHODH, HAAO TDP1 3910/4885ALDH1A1 956/4885TSHR 4028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.